From beta to alpha: understanding the next generation of radiopharmaceutical therapies

Radiopharmaceutical innovation is accelerating, with multiple promising agents approved or in development that have the potential to reshape the cancer treatment landscape. This article provides a clear, clinician-focused overview of where the field currently stands and where it is heading, for an audience increasingly likely to encounter these therapies in their practice.

The article outlines the key differences between beta-emitting radiopharmaceuticals, which have so far dominated the field, and targeted alpha therapies, which represent its emerging frontier. While alpha therapies offer significant potential, particularly in metastatic and hard-to-treat disease, their clinical translation presents distinct challenges that must be overcome for them to become mainstream treatments. By exploring both the hurdles and the opportunities, the article highlights what these innovations could mean for patients, clinicians and the future of cancer care.

To download and read this article as a pdf please sign up to our newsletter.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.